ProBioGen will oversee the design, construction, and operation of the 4,600-square-meter GMP manufacturing unit
The Ma’anshan site approval covers pastilles, oral liquids, and powders
Accelerating RNA-based therapeutic solutions for customers through co-development of products and formulation support
The cGMP-4 facility will further strengthen the company's ability to serve global partners
Phase 1 has a total reactor capacity of 440 kL with 63 reactors
WIDAPLIK is the first and only FDA-approved triple combination medication for use as an initial therapy in patients likely to need multiple drugs to achieve blood pressure goals
The first pillar is advanced manufacturing, focused on upgrading existing CDMO
Collaboration reinforces Boehringer Ingelheim’s expertise in microbial contract development and manufacturing
Subscribe To Our Newsletter & Stay Updated